Cargando…
Synthesis, Biological Activity and Molecular Docking Studies of Novel Nicotinic Acid Derivatives
In our research, we used nicotinic acid as a starting compound, which was subjected to a series of condensation reactions with appropriate aldehydes. As a result of these reactions, we were able to obtain a series of twelve acylhydrazones, two of which showed promising activity against Gram-positive...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8911400/ https://www.ncbi.nlm.nih.gov/pubmed/35269966 http://dx.doi.org/10.3390/ijms23052823 |
_version_ | 1784666792978808832 |
---|---|
author | Paruch, Kinga Biernasiuk, Anna Khylyuk, Dmytro Paduch, Roman Wujec, Monika Popiołek, Łukasz |
author_facet | Paruch, Kinga Biernasiuk, Anna Khylyuk, Dmytro Paduch, Roman Wujec, Monika Popiołek, Łukasz |
author_sort | Paruch, Kinga |
collection | PubMed |
description | In our research, we used nicotinic acid as a starting compound, which was subjected to a series of condensation reactions with appropriate aldehydes. As a result of these reactions, we were able to obtain a series of twelve acylhydrazones, two of which showed promising activity against Gram-positive bacteria (MIC = 1.95–15.62 µg/mL), especially against Staphylococcus epidermidis ATCC 12228 (MIC = 1.95 µg/mL). Moreover, the activity of compound 13 against the Staphylococcus aureus ATCC 43300 strain, i.e., the MRSA strain, was MIC = 7.81 µg/mL. Then, we subjected the entire series of acylhydrazones to a cyclization reaction in the acetic anhydride, thanks to which we were able to obtain twelve new 3-acetyl-2,5-disubstituted-1,3,4-oxadiazoline derivatives. Obtained 1,3,4-oxadiazolines were also tested for antimicrobial activity. The results showed high activity of compound 25 with a 5-nitrofuran substituent, which was active against all tested strains. The most promising activity of this compound was found against Gram-positive bacteria, in particular against Bacillus subtilis ATCC 6633 and Staphylococcus aureus ATCC 6538 (MIC = 7.81 µg/mL) and ATCC 43300 MRSA strains (MIC = 15.62 µg/mL). Importantly, the best performing compounds did not show cytotoxicity against normal cell lines. It seems practical to use some of these compounds or their derivatives in the future in the prevention and treatment of infections caused by some pathogenic or opportunistic microorganisms. |
format | Online Article Text |
id | pubmed-8911400 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-89114002022-03-11 Synthesis, Biological Activity and Molecular Docking Studies of Novel Nicotinic Acid Derivatives Paruch, Kinga Biernasiuk, Anna Khylyuk, Dmytro Paduch, Roman Wujec, Monika Popiołek, Łukasz Int J Mol Sci Article In our research, we used nicotinic acid as a starting compound, which was subjected to a series of condensation reactions with appropriate aldehydes. As a result of these reactions, we were able to obtain a series of twelve acylhydrazones, two of which showed promising activity against Gram-positive bacteria (MIC = 1.95–15.62 µg/mL), especially against Staphylococcus epidermidis ATCC 12228 (MIC = 1.95 µg/mL). Moreover, the activity of compound 13 against the Staphylococcus aureus ATCC 43300 strain, i.e., the MRSA strain, was MIC = 7.81 µg/mL. Then, we subjected the entire series of acylhydrazones to a cyclization reaction in the acetic anhydride, thanks to which we were able to obtain twelve new 3-acetyl-2,5-disubstituted-1,3,4-oxadiazoline derivatives. Obtained 1,3,4-oxadiazolines were also tested for antimicrobial activity. The results showed high activity of compound 25 with a 5-nitrofuran substituent, which was active against all tested strains. The most promising activity of this compound was found against Gram-positive bacteria, in particular against Bacillus subtilis ATCC 6633 and Staphylococcus aureus ATCC 6538 (MIC = 7.81 µg/mL) and ATCC 43300 MRSA strains (MIC = 15.62 µg/mL). Importantly, the best performing compounds did not show cytotoxicity against normal cell lines. It seems practical to use some of these compounds or their derivatives in the future in the prevention and treatment of infections caused by some pathogenic or opportunistic microorganisms. MDPI 2022-03-04 /pmc/articles/PMC8911400/ /pubmed/35269966 http://dx.doi.org/10.3390/ijms23052823 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Paruch, Kinga Biernasiuk, Anna Khylyuk, Dmytro Paduch, Roman Wujec, Monika Popiołek, Łukasz Synthesis, Biological Activity and Molecular Docking Studies of Novel Nicotinic Acid Derivatives |
title | Synthesis, Biological Activity and Molecular Docking Studies of Novel Nicotinic Acid Derivatives |
title_full | Synthesis, Biological Activity and Molecular Docking Studies of Novel Nicotinic Acid Derivatives |
title_fullStr | Synthesis, Biological Activity and Molecular Docking Studies of Novel Nicotinic Acid Derivatives |
title_full_unstemmed | Synthesis, Biological Activity and Molecular Docking Studies of Novel Nicotinic Acid Derivatives |
title_short | Synthesis, Biological Activity and Molecular Docking Studies of Novel Nicotinic Acid Derivatives |
title_sort | synthesis, biological activity and molecular docking studies of novel nicotinic acid derivatives |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8911400/ https://www.ncbi.nlm.nih.gov/pubmed/35269966 http://dx.doi.org/10.3390/ijms23052823 |
work_keys_str_mv | AT paruchkinga synthesisbiologicalactivityandmoleculardockingstudiesofnovelnicotinicacidderivatives AT biernasiukanna synthesisbiologicalactivityandmoleculardockingstudiesofnovelnicotinicacidderivatives AT khylyukdmytro synthesisbiologicalactivityandmoleculardockingstudiesofnovelnicotinicacidderivatives AT paduchroman synthesisbiologicalactivityandmoleculardockingstudiesofnovelnicotinicacidderivatives AT wujecmonika synthesisbiologicalactivityandmoleculardockingstudiesofnovelnicotinicacidderivatives AT popiołekłukasz synthesisbiologicalactivityandmoleculardockingstudiesofnovelnicotinicacidderivatives |